Finanzen von Trevi Therapeutics Inc (TRVI)TRVITrevi Therapeutics Inc

Evaluating the bottom line, Trevi Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -19.66%, provide a clear picture of how effectively TRVI converts its operational activities into shareholder value.

In the context of the broader market, TRVI competes directly with industry leaders such as URGN and SEPN. With a market capitalization of $1.82B, it holds a significant position in the sector. When comparing efficiency, TRVI's gross margin of N/A stands against URGN's 90.93% and SEPN's 100.00%. Such benchmarking helps identify whether Trevi Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Trevi has shown a significant increase in cash reserves, with current assets of $325 million in Q2 2026, which is crucial for funding its clinical trials and operations.